The network of methotrexate toxicity;A teia de toxicidade do metotrexato

Acta Reumatologica Portuguesa

Volumn 34, Issue 1, 2009, Pages 11-34

  Neves, Clarinda ^a   Jorge, Rosa ^b   Barcelos, Anabela ^c  

^a Interna Complementar de Medicina Interna ^*  (Portugal)

^b Directora do Serviço de Medicina 2

^c Hospital Infante D Pedro EPE   (Portugal)

Author keywords

Adverse effects; Methotrexate; Rheumatoid arthritis; Toxicity

Indexed keywords

ANTIRHEUMATIC AGENT; FOLIC ACID; METHOTREXATE;

BONE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; CONGENITAL MALFORMATION; GASTROINTESTINAL DISEASE; HUMAN; LUNG DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; TOXIC HEPATITIS;

ABNORMALITIES, DRUG-INDUCED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; FOLIC ACID; GASTROINTESTINAL DISEASES; HEPATITIS, TOXIC; HUMANS; LUNG DISEASES; METHOTREXATE; SKIN DISEASES;

EID: 67649803337     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheumatism 2004;50:1370-1382.
2. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951;221:176-182.
3. Rau R, Herborn G. Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2004;22:83-94.
4. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Reumatol 1984;11:760-763.
5. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin Bl. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489-496.
6. Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy on psoriathic arthritis: a double blind study on 21 patients. JAMA 1964;189:743-747.
7. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:179-185.
8. Kremer JM, Alarcón GS, Lightfoot RW Jr et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-328.
9. Kinder AJ, Hassel AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 2005;44:61-66.
10. Alarcón GS, Tracy IC, Strand GM, Singh K, Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995;54:708-712.
11. Tian H, Cronstein BN. Understanding the mechanisms of action os methotrexate. Bull NYU Hosp Jt Dis 2007;65:168-173.
12. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheumatism 1998;27:277-292.
13. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006;58:473-492.
14. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-172.
15. Borchers AT, Keen CL, Cheema GS, Gershwin ME. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheumatism 2004;34:465-483.
16. Kremer JM, Galigan J, Streckfuss A, Kamen B. Methotreate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-835.
17. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology 2004;43:267-271.
18. Cutolo M, Sulli A,Pizzorni C, Seriolo C, Siraub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rhem Dis 2001;60:729-735.
19. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005;54:273-280.
20. Kalantzis A, Marshman Z, Falconer DT, Morgan PR, Odell EW. Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:52-62.
21. Rau R, Schleusser B, Herborn G, Karger T. Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997;24:1881-1889.
22. Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures JP. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 11 cases. J Rheumatol 1991;18:1323-1327.
23. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis. J Rheumatology 1990;17;994-1002.
24. Stamp L, Roberts R, Kennedy M, Barclay M, O'Donnel J, Chapman P. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother 2006;60:678-687.
25. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirrheumatic drugs. Arthritis Rheumatism 1993;36:297-306.
26. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259.
27. McKendry RJR. The remarkable spectrum of methotrexate toxicities. Rheumatic Disease Clinics of North America 1997;23:939-954.
28. La Montagna G, Tirri R, Vitello R et al. Safety of methotrexate in rheumatoid arthritis: a retrospective cohort sudy in clinical practice. Reumatismo 2006;58:261-267.
29. Weinblatt ME. Methotrexate in rheumatoid arthritis: toxicity issues. British Journal Rheumatology 1996;35:403-406.
30. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheumatism 1989;32:1592-1596.
31. Hoekstra M, van Ede AE, Haagsma CJ et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-426.
32. Kremer JM, Phelps CT. Long-term propective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheumatism 1992;35:138-145.
33. Yoshida T, Hirakata M. Therapeutis benefits of irsogladine maleate on aphtous stomatitis induced by methotrexate in rheumatoid arthritis. J Rheumatology 2003;30:2082-2083.
34. Van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, doubleblind, placebo-controlled study. Arthritis Rheum 2001;44:1515-1524.
35. Phillips CA, Cera PJ, Mangan TF, Newman ED. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992;19:229-233.
36. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989;32:121-127.
37. Aponte J, Petrelli M. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Reum 1988;31:1457-1464.
38. Walker AM, Funch D, Dreyer NA et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993;36:329-335.
39. Alarcón GS. Methotrexate use in rheumatoid arthritis. A clinician's perspective. Immunopharmacology 2000;47:259-271.
40. Laharie D, Terrebone E, Vergniol J et al. The liver and methotrexate. Gastroenterol Clin Biol 2008;32:134-142.
41. Kent PD, Luthra HS, Michet C Jr. Risk factors for methotrexate-induced abdnormal laboratory manitoring results in patients with rheumatoid arthritis. J Rheumatol 2004;31:1727-1731.
42. Hakim NS, Kobienia B, Benedetti E, Bloomer J, Payne WD. Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. Int Surg 1998;83:224-225.
43. Goerttler E, Kutzner MD, Peter HH, Requena L. Methotrexate-induced papular eruption in patients with rheumatic diseases: a distinctive adverse cutaneous reaction produced by methotrexate in ap-tients with collagen vascular diseases. J Am Acad dermatol 1999;40:702-707.
44. Del Pozo J, Martinez W, Garcia-Silva J, Almagro M, Peña-Penabad C, Fonseca E. Cutaneous ulceration as a sign of methotrexate toxicity. Eur J Dermatology 2001;11:450-452.
45. Simonart T, Durez P, Margaux J, Van Geertruyden J, Goldschmidt D, Parent D. Cutaneous necrotizing vasculitis after low dose methotrexate therapy for rheumatoid arthritis: a possible manifestation of methotrexate hypersensitivity. Clin Rheumatol 1997;16:623-625.
46. Ahmed SS, Arnett FC, Smith CA, Ahn C, Reveille JD. The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis. Medicine (Baltimore) 2001;80:271-278.
47. García-Patos, V. Rheumatoid nodule. Semin Cutan Med Surg 2007;26:100-107.
48. Berris B, Houpt JB, Tenenbaum J. Accelerated nodulosis in a patient with psoriasis and arthritis durins treatment with methotrexate. J Rheumatol 1995;22:2359-2360.
49. Rivero MG, Salvatore AJ, Gómez-Puerta JA et al. Accelerated nodulosis during methotrexate therapy in a patient with systemic lupus erythematosus and Jaccoud's arthropathy. Rheumatology (Oxford) 2004;43: 1587-1588.
50. Jang KA, Choi JH, Moon KC, Yoo B, Sung KJ, Koh JK. Methotrexate nodulosis. J Dermatol 1999;26:460-464.
51. Falcini F, Taccetti G, Ermini M et al. Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:175-178.
52. Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy. 2002;22:1157-1162.
53. Dash S, Seibold JR, Tiku ML. Successful treatment of methotrexate induced modulosis with D-penicillamine. J Rheumatol 1999;26:1396-1399.
54. Abraham Z, Rozenbaum M, Rosner I. Colchicine therapy for low-dose-methotrexate-induced accelerated nodulosis in a rheumatoid arthritis patient. J Dermatol 1999;26:691-694.
55. Karam NE, Roger L, Hankins LL, Reveille JD. Rheumatoid nodulosis of the meninges. J Rheumatol 1994;21:1960-1963.
56. Sørensen WT, Møller-Andersen K, Behrendt N. Rheumatoid nodules of the larynx. J Laryngol Otol 1998;112:573-574.
57. Ohosone Y, Okano Y, Kameda H et al. Toxicity of lowdose methotrexate in rheumatoid arthritis - clinical characteristics in patients with MTX-induced pancytopenia and interstitial pneumonitis. Ryumachi 1997;37:16-23.
58. Sosin M, Handa S. Low dose methotrexate and bone marrow suppression. BMJ 2003;326:266-267.
59. Moisa A, Fritz P, Benz D, Wehner H-D. Iatrogenicallyrelated, fatal methotrexate intoxication: a series of four cases. Forensic Science International 2006;156:154-157.
60. MacDonald DR. Neurologic complications of chemotherapy. Neurol Clin 1991;9:955-967.
61. Raghavendra S, Nair MD, Chemmanam T, Krishnamoorthy T, Radhakrishnan VV, Kuruvilla A. Disseminated necrotizing l
62. Sommer WH, Ganiere V, Gachoud D et al. Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. Scand J Rheumatol 2008;37:306-309.
63. Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis reum 1989;32:770-775.
64. Sbeity ZH, Baydoun L, Schidt S, Loeffler KU. Visual field changes in methotrexate therapy. Case report and review of the literature. J Med Liban 2006;54:164-167.
65. LeMense GP, Sahn SA. Opportunistic infection during treatment with lower dose methotrexate. Am J Respire Crit Care Med 1994;150:258-260.
66. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respr J 2000;15:373-381.
67. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005;4:723-730.
68. Ikuni N, Iwami S, Kasai S, Tokuda H. Noncardiogenic pulmonary edema in low-dose oral methorexate therapy. Internal Medicine 2004;43:846-851.
69. Alarcón GS, Kremer JM, Macaluso M et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, casecontrol study. Methotrexate-Lung Study Group. Ann Intern Med 1997;127:356-364.
70. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporatings HRCT scanning and pulmonary function tests. Rheumatology 2002;41:262-267.
71. Cottin V, Tébib J, Massonnet B, Souquet OJ, Bernard JP. Pulmonary function in patients receiving longterm low-dose methotrexate. Chest 1996;109:933-938.
72. Belin V, Tebib J, Vignon E. Cytomegalovirus infection in a patient with rheumatoid arthritis. Joint Bone Spine 2003;70:303-306.
73. Roy V, Hammerschmidt DE. Disseminated histoplasmosis following prolonged low-dose methotrexate therapy. AM J Hematol 2000;63:59-60.
74. Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007;25:888-889.
75. Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapyin a patient with rheumatoid arthritis. Rheumatology 2001;40:341-342.
76. Kawabe Y, Eguchi K, Tsuboi M et al. Untoward effects of low dose methotrexate therapy in rheumatoid arthritis. Ryuacho 1996;36:514-521
77. Takayanagi N, Tsuchiya Y, Tokunaga D et al. Pulmonary infections in patients with rheumatois arthritis. Nihon Kokyuki Gakkai Zasshi. 2007;45:465-473.
78. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214-217.
79. Perhala RS, Wilke WS, Clugh JD, Segal AM. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexae versus those not treated with methotrexate. Arthritis Rheum 1991;34:146-152.
80. Murata K, Yasuda T, Ito H, Yoshida M, Shimizu M, Nakamura T. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Mod Rheumatol 2006;16:14-19.
81. Pieringer H, Stuby U, Biesenbach G. The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:1217-1220.
82. Rheumatoid Arthritis Study Group of the Portuguese Society of Rheumatology. Portuguese guidelines for the use of biological agents in rheumatoid arthritis -December 2007 update. Acta Reumatol Port 2007;32:363-366.
83. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999;92:551-563.
84. Abe K, Mitsuka T, Kanamori S, Yamashita K, Yamaoka A. Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis. Mod Reumatol 2007;17:511-513.
85. French AE Koren G. Effect of methotrexate on male fertility. Can Fam Physician 2003;49:577-578.
86. Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatology 1995;22:38-40.
87. Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 1998;57:110-113.
88. Izzedine H, Launay-Vacher V, Karie S, Caramella C, de Person F, Deray G. Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 2005;64:315-319.
89. Jardine DL, Colls BM. Hodgkin's disease following methotrexate therapy for rheumatoid arthritis. N Z Med J 2002;115:293-294.
90. Baird RD, van Zyl-Smit RN, Dilke T, Scott SE, Rassam SM. Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol 2002;118:567-568.
91. Dubin Kerr L, Troy K, Isola L. Temporal association between the use of methotrexate and development of leukemia in 2 patients with rheumatoid arthritis. J Rheumatol 1995;22:2356-2358.
92. Thonhofer R, Gaugg M, Kriessmayr M, Neumann HJ, Erlacher L. Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis 2005;64:1098-1099.
93. Preston SJ, Diamond T, Scott A, Laurent MR. Methotrexate osteopathy in rheumatic disease. Annals Rheumatic Diseases 1993;52:582-585.
94. Stevens H, Jacobs JW, Van Rijk PP, De Klerck JM. Methotrexate osteopathy demonstrated by Technetium-99m HDP bone scintigraphy. Clin Nucl Med 2001;26:389-391.
95. Alonso-Bartolome P, Martinez-Taboada VM, Canga A, Blanco R. Medial tibial stress syndrome due to methotrexate osteopathy. Ann Rheum Dis 2006;65:832-833.
96. Bologna C, Edno L, Anaya JM et al. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994;37:1770-1773.
97. May KP, West SG, MacDermott MT, Huffer WE. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 1994;37:201-206.
98. Cegie_a U, _liwi_ski L, Kaczmarczyk-Sedlak I, Folwarczna J. Pharmacol Rep 2005;57:504-514.
99. Minaur NJ, Jeffeiss C, Bhalla AK, Beresford JN. Methotrexae in the treatment of rheumatoid arthritis. I. In vitro effects on cells of the osteoblast lineage. Rheulatology (Oxford) 2002;41:735-740.
100. Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002;41:741-749.
101. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997;24:1489-1494.
102. Patel S, Patel G, Johnson D, Ogunremi L, Barron J. Effect of low dose weekly methotrexate on bone mineral density and bone turnover. Ann Rheum Dis 2003;62:186-187.
103. Cranney AB, McKendry RJ, Wells GA et al. The effect of low dose methotrexate on bone density. J Rheumatol 2001;28:2395-2399.
104. Di Munno O, Mazzantini M, Sinigaglia L et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 2004;31:1305-1309.
105. Rozin AP. Is methotrexate osteopathy a form of bone idiosyncrasy? Ann Rheum Dis 2003;62:1123; author reply 1124.
106. Halla JT, Hardin JG. Underrecognized postdosing reactions to methotrexate in patients with rheumatoid arthritis. J Reumathology 1994;21:1224-1226.
107. Pham T, Gossec L, Constantin A et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:379-387.
108. Boers GH. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000;26:291-295.
109. El Bouchti I, Sordet C, Kuntz JL, Sibilia J. Severe atherosclerosis in rheumatoid arthritis and hyperhomocysteinemia: is there a link? Joint Bone Spine 2008;75:499-501.
110. Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving lowdose methotrexate treatment. Clin Pharmacol Ther 1989;46:510-520.
111. Naranjo A, Sokka T, Descalzo MA et al, QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthriti Res Ther 2008;10:R30.
112. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geboreck P. Influence of methotrexate, THF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:106-111.
113. Brezinschek HP, Hofstaetter T, Leeb BF, Haindl P, Graninger WB. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol 2008;20:295-299.
114. Kasapçopur O, Cullu F, Kamburo_lu-Goksel A et al. Hepatitis B Vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1128-1130.
115. Fernández-Espartero MC, Rodríguez M, de la Mata J. Methotrexate-induced nephrogenic diabetes insipidus: first case report. Rheumatology (Oxford) 2002;41:233-234.
116. Van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 2007;25:480-485.
117. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121: 833-841.
118. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reduzing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;15:36-43.
119. van Ede AE, Laan RFJM, Blom HJ et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002;41:658-665.
120. Hoekstra M, Haagsma CJ, Doelman CJ, van de Laar MA. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 2005;64:141-143.
121. Shahin AA, Ismail MM, Saleh AM, Moustafa HA, Aboul-Ella AA, Gabr HM. Protective effect of folinic acid on low-dose methotrexate genotoxicity. Z Rheumatol 2001;60:63-68.
122. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991;50:913-914.
123. Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis 2006;65:1121-1123.
124. Weisman MH, Furst DE, Park GS et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006;54:607-612.
125. Bohanec Grabar P, Logar D, Lestan B, Dol_an V. Genetic determinants of methotrexate toxicityin rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008;64:1057-1068.
126. Yang CP, Kuo MC, Guh JY, Chen HC. Pancytopenia after low dose methotrexate therapy n a hemodialysis patient: case report and review of literature. En Fail 2006;28:95-97.
127. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008. Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum 2008;59:762-784.
128. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2008 [Epub ahead of print].
129. Canhao H, Santos MJ, Costa L, Bogas M, Mourao AF, Machado P, Fonseca JE, Silva JAP. Recomendações portuguesas para utilização de metotrexato no tratamento de doenças reumáticas. Acta Reumatol Port 2009;78-95.